InspireMD, an Israeli medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarction, announced positive three-year results from the extended follow up trial of patients suffering from acute coronary syndromes. Acute Myocardial Infarction is commonly known as a heart attack and results from the interruption of blood supply to the heart. According to the company, the results showed that the safety and efficacy of its MGuard stents were maintained at three years.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments